The spin-off of the University of Valencia Science Park, led by Pilar and Marisa Domingo Calap, has been awarded in the health and biotechnology category. The biotechnology company is focused on combating bacterial resistance through the use of bacteriophages
The newspaper Expansión has once again recognized the best start-ups in Spain. At an event held at the World Trade Center in Barcelona, the EXPANSIÓN Start Up Awards were presented. These awards have become a reference in the sector and serve to put on the map the most cutting-edge projects currently being developed in Spain.
In this seventh edition, 18 emerging projects have been distinguished from a total of 101 applications received, corresponding to 74 start ups. Each applicant was eligible for two of the six categories in the competition, so there are more entries than participating firms.
Among them, Evolving Therapeutics has been one of the winners. This company, located in the business area of the University of Valencia Science Park (PCUV) and within the AgrotecUV incubator, has been awarded in the category health and bioteconology. The company works under the One Health paradigm, developing innovative and environmentally safe solutions that improve the health of people, animals and plants.
Don’t miss the interview with Pilar Domingo Calap in our podcast "La Bombilla de Livermore"
About Evolving Therapeutics
Evolving Therapeutics is a spin-off of the University of Valencia (UV), founded in 2023. It is located in the PCUV, specifically at the Institute of Integrative Systems Biology (I2SysBio) and founded by Pilar Domingo Calap and Marisa Domingo Calap. The company was recently awarded at the Bioval 2025 Awards.
Its mission is to develop biotechnological solutions to combat pathogenic bacteria, especially those that are multi-resistant to antibiotics, using bacteriophages (or "phages"), i.e., viruses that infect only bacteria. Evolving Therapeutics works under the One Health paradigm, so their technology is designed to be applied not only in human health, but also in animal, agricultural (plant) and even environmental health.
Its services include isolation of specific phages from problem bacteria; characterisation and optimisation of these phages; development of "cocktails" of phages adapted to particular strains; rapid diagnosis solutions for target bacteria; and customized treatments that attack only the pathogen, respecting healthy microbiota and reducing environmental pollution. In particular, one of its lines is aimed at combating resistant bacteria such as multi-resistant strains of Staphylococcus aureus, a particularly dangerous and difficult to treat pathogen.
Source: Expansión
Recent Posts